The research collaboration will focus on developing immunomodulatory lead compounds for cancer treatment.
Evotec chief operating officer Dr Mario Polywka said; "We look forward to continue working with Apeiron on this important project. The collaboration highlights the strength of Evotec’s phenotypic screening capabilities to identify novel mechanisms and hits in important therapeutic areas."
Apeiron Biologics will contribute its in-vitro and in-vivo pharmacology knowledge to the research, while Evotec will provide medicinal chemistry as well as chemical proteomics.
The collaboration occured following the successful outcome of a phenotypic high throughput screen, which Apeiron Biologics previously commissioned to Evotec.
Apeiron Biologics chief executive officer Dr Hans Loibner said the company is looking forward to refining the target compounds in the collaboration using its own immunological expertise.
"There is no doubt that immunomodulatory compounds like these carry huge therapeutic and commercial potential," Loibner said.
Financial details of the transaction were not disclosed.